Skip to main content

Paul Langlie Martin, MD, PhD

Professor of Pediatrics
Chief, Division of Pediatric Blood and Marrow Transplantation
Member of the Duke Cancer Institute
Campus mail: 1400 Morrene Rd, Durham, NC 27705
Phone: (919) 668-1124
Email address: paul.martin@duke.edu

For most of my career in Pediatric Hematology/Oncology I have focused on the use of stem cell transplant for the treatment of pediatric leukemias (ALL, AML, CML and JMML) and other non-malignant blood disorders, such as thalassemia, hemaphagocytic disorders, Wiskott-Aldrich, aplastic anemia, Diamond-Blackfan Anemia, as well as inherited metabolic diseases. In addition to focusing on determining the best use of stem cell transplants for these disorders, I have also been involved in clinical research investigating the prevention and treatment of transplant related morbidity, particularly veno-occlusive disease of the liver, infections and diffuse alveolar hemorrhage. As study chair for the Children's Oncology Group protocol 9904, I was involved in the development, implementation and analysis of a large, international frontline study of childhood acute lymphoblastic leukemia. Results from this study show that a significant number of children with certain favorable cytogenetic abnormalities in their leukemic cells and who have a rapid response to their initial chemotherapy can expect to have a >95% chance of cure when treated with relatively low intensity chemotherapy.

Education and Training

  • Fellow, Pediatric Hematology/Oncology, Pediatrics, Yale University, 1989 - 1992
  • Resident, Pediatrics, Yale University, 1988 - 1989
  • Intern, Pediatrics, Yale University, 1987 - 1988
  • Ph.D., Washington University in St. Louis, 1987
  • M.D., Washington University in St. Louis, 1987

Publications

Jacobsohn, David A., Michael R. Loken, Mingwei Fei, Alexia Adams, Lisa Eidenschink Brodersen, Brent R. Logan, Kwang Woo Ahn, et al. “Outcomes of Measurable Residual Disease in Pediatric Acute Myeloid Leukemia before and after Hematopoietic Stem Cell Transplant: Validation of Difference from Normal Flow Cytometry with Chimerism Studies and Wilms Tumor 1 Gene Expression..” Biol Blood Marrow Transplant 24, no. 10 (October 2018): 2040–46. https://doi.org/10.1016/j.bbmt.2018.06.010.

Full Text

Kelly, Matthew S., Lisa Spees, Richard Vinesett, Andre Stokhuyzen, Lauren McGill, Alan D. Proia, Kirsten Jenkins, Mehreen Arshad, Patrick C. Seed, and Paul L. Martin. “Utility of Autopsy among Pediatric Allogeneic Hematopoietic Stem Cell Transplant Recipients: One Last Chance to Learn?.” Biol Blood Marrow Transplant 24, no. 9 (September 2018): 1861–65. https://doi.org/10.1016/j.bbmt.2018.05.030.

Full Text

Churchman, Michelle L., Maoxiang Qian, Geertruy Te Kronnie, Ranran Zhang, Wenjian Yang, Hui Zhang, Tobia Lana, et al. “Germline Genetic IKZF1 Variation and Predisposition to Childhood Acute Lymphoblastic Leukemia..” In Cancer Cell, 33:937-948.e8, 2018. https://doi.org/10.1016/j.ccell.2018.03.021.

Full Text

Parikh, Suhag, Joel A. Brochstein, Stephen Wease, Paul L. Martin, Mitchell E. Horwitz, Aurelie Schwarzbach, and Joanne Kurtzberg. “A Novel Therapy for Sickle Cell Disease (SCD): Co-Transplantation of Nicord (R) [Ex Vivo Expanded Umbilical Cord Blood (UCB) Progenitor Cells with Nicotinamide] and an Unmanipulated Unrelated UCB Graft Leads to Successful Engraftment and Cure of Severe SCD.” In Biology of Blood and Marrow Transplantation, 24:S157–58. ELSEVIER SCIENCE INC, 2018.

Scholars@Duke

Qian, Maoxiang, Xueyuan Cao, Meenakshi Devidas, Wenjian Yang, Cheng Cheng, Yunfeng Dai, Andrew Carroll, et al. “TP53 Germline Variations Influence the Predisposition and Prognosis of B-Cell Acute Lymphoblastic Leukemia in Children..” J Clin Oncol 36, no. 6 (February 20, 2018): 591–99. https://doi.org/10.1200/JCO.2017.75.5215.

Full Text

Maude, Shannon L., Theodore W. Laetsch, Jochen Buechner, Susana Rives, Michael Boyer, Henrique Bittencourt, Peter Bader, et al. “Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia..” N Engl J Med 378, no. 5 (February 1, 2018): 439–48. https://doi.org/10.1056/NEJMoa1709866.

Full Text

Patel, Sachit A., Heather A. Allewelt, Jesse D. Troy, Paul L. Martin, Timothy A. Driscoll, Vinod K. Prasad, Joanne Kurtzberg, Kristin M. Page, and Suhag H. Parikh. “Durable Chimerism and Long-Term Survival after Unrelated Umbilical Cord Blood Transplantation for Pediatric Hemophagocytic Lymphohistiocytosis: A Single-Center Experience..” Biol Blood Marrow Transplant 23, no. 10 (October 2017): 1722–28. https://doi.org/10.1016/j.bbmt.2017.06.013.

Full Text

Wang, Hong, Man Huang, Ying Zhao, Jia-Qian Qi, Chun Chen, Ya-Qiong Tang, Hui-Ying Qiu, et al. “Recombinant Human Thrombopoietin Promotes Platelet Engraftment and Improves Prognosis of Patients with Myelodysplastic Syndromes and Aplastic Anemia after Allogeneic Hematopoietic Stem Cell Transplantation.” Biology of Blood and Marrow Transplantation 23, no. 10 (October 2017): 1678–84. https://doi.org/10.1016/j.bbmt.2017.06.010.

Full Text

Maude, S. L., S. A. Grupp, M. A. Pulsipher, S. Rives, G. D. Myers, M. R. Verneris, J. Buechner, et al. “ANALYSIS OF SAFETY DATA FROM 2 MULTICENTER TRIALS OF CTL019 IN PEDIATRIC AND YOUNG ADULT PATIENTS WITH RELAPSED/REFRACTORY (R/R) B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA (B-ALL).” In Haematologica, 102:197–98. FERRATA STORTI FOUNDATION, 2017.

Scholars@Duke

Buechner, J., S. A. Grupp, S. L. Maude, M. Boyer, H. Bittencourt, T. W. Laetsch, P. Bader, et al. “GLOBAL REGISTRATION TRIAL OF EFFICACY AND SAFETY OF CTL019 IN PEDIATRIC AND YOUNG ADULT PATIENTS WITH RELAPSED/REFRACTORY (R/R) ACUTE LYMPHOBLASTIC LEUKEMIA (ALL): UPDATE TO THE INTERIM ANALYSIS.” In Haematologica, 102:178–178. FERRATA STORTI FOUNDATION, 2017.

Scholars@Duke

Pages